Home

Newly Defined Cancer Driver FOXA1

FOXA1 is a principal oncogene in AR-dependent prostate cancer; FOXA1 alterations can be stratified into three main structural classes.

Promising New Compounds to Treat Advanced Prostate Cancer

The landscape of circular RNA in cancer

Building a compendium of circRNA in cancer that could serve as a valuable resource for the development of circRNAs as diagnostic or therapeutic targets across cancer types.

Michigan Legacy Tissue Program

Read about the Michigan Legacy Tissue Program by MCTP faculty member, Rohit Mehra.

Dr. Chinnaiyan Receives Outstanding Investigator Award

A new grant to Dr. Arul Chinnaiyan will provide long-term support to explore precision oncology

CDK12 inactivation defines a new class of prostate cancer

Discovery of a novel prostate cancer lncRNA

Researchers at MCTP identified a novel long noncoding RNA, ARLNC1 that is strongly associated with AR signaling in prostate cancer progression.

Discovery of a novel non-coding RNA, THOR

THOR is an ultraconserved lncRNA that exhibits expression exclusively in testis and a broad range of human cancers.

New FISH Assays to Aid Renal Cancer Diagnosis

New clinical fluorescence in situ hybridization (FISH) assays to detect TFE3 and TFEB translocations offered through UM genitourinary FISH service (at MLabs).

Clinical genomics of metastatic cancer

In one of the largest and most comprehensive efforts to examine the genetic and molecular landscape of advanced cancer, researchers at the University of Michigan Comprehensive Cancer Center sequenced the DNA and RNA of 500 patients with metastatic cancer.

Precision medicine: view from two sides

A review of MI-ONCOSEQ clinical sequencing program at Michigan Medicine

Immunohistochemical Detection of HLRCC Markers

Immunohistochemical evaluation of markers suggest a role for prospective FH IHC to screen cutaneous leiomyoma patients for HLRCC.

A new therapeutic approach to target prostate cancer

New research suggests a novel strategy to target a genetic anomaly that occurs in half of all prostate cancers.

Dr. Chinnaiyan featured in the journal, Cancer

Dr. Chinnaiyan's research career featured in an article in the journal, Cancer

Recent MCTP Awardees

Several MCTP members were recent award recipients

MCTP Wins OSEH Safety First Award

MCTP wins Occupational Safety & Environmental Health Safety First Recognition Award.

MCTP Award Recipients

MCTP members were recipients of several awards.

A novel KRAS-AGO2 interaction in cancer

Discovery of a functional KRAS-AGO2 interaction may have implications for novel therapeutic strategy for KRAS-driven cancers.

AACR visits Washington DC

AACR leadership and members including Dr. Arul Chinnaiyan meet with FDA officials and Vice President's senior staff.

Genetic landscape of pediatric cancers

MCTP researchers and collaborators have published the results from the first 102 pediatric patients enrolled in the PEDS-ONCOSEQ clinical sequencing study.

Mutational landscape of metastatic CRPC

New study is the first comprehensive molecular landscape of metastatic castrate-resistant prostate cancer.

Targeting MLL complex in CRPC

MLL-menin inhibitor disrupts AR-MLL complex interaction that results in blocking AR signaling and inhibiting the growth of castration-resistant tumors.

Drs. Mehra and Palanisamy featured in "Researcher in the Spotlight"

MCTP researchers, Nalla Palanisamy and Rohit Mehra, were featured in Advanced Cell Diagnostics' "Researcher in the Spotlight" newsletter where they discussed their work.

Long Non-Coding RNA landscape in cancer

MCTP researchers analyzed the global landscape of a portion of the genome that has not been previously well-explored – long non-coding RNAs (lncRNAs).

Drs. Chinnaiyan and Wang elected to NAI

Drs. Arul Chinnaiyan and Shaomeng Wang were named 2014 National Academy of Inventors (NAI) Fellows.